Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

830
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
830
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

974
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
974
Analgesia and Pain Management01:25

Analgesia and Pain Management

2.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.3K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

1.2K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.2K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.2K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.2K
Drug Classes and Categories01:25

Drug Classes and Categories

3.2K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential neural responses to rhythmic and patterned TMS protocols: Insights from EEG spectral analysis.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

The effect of older age on outcomes of rTMS treatment for treatment-resistant depression.

International psychogeriatrics·2025
Same author

Foreseeably Early Deaths in Patients With Psychiatric Disorders: Challenges in Caring for Patients Manifesting Likely Fatal Trajectories.

The Journal of nervous and mental disease·2024
Same author

Words Matter: Why Distinguishing Medical Aid in Dying From Suicide Should Matter to a Consultation-Liaison Psychiatrist.

Journal of the Academy of Consultation-Liaison Psychiatry·2024
Same author

The role of sex and age in the differential efficacy of 10 Hz and intermittent theta-burst (iTBS) repetitive transcranial magnetic stimulation (rTMS) treatment of major depressive disorder (MDD).

Journal of affective disorders·2024
Same author

The effect of older age on outcomes of rTMS treatment for treatment-resistant depression.

International psychogeriatrics·2024

Related Experiment Video

Updated: Feb 23, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

582

Cannabinoids in Medical Practice.

Thomas B Strouse1

  • 1Department of Psychiatry, David Geffen UCLA School of Medicine, Los Angeles, California.

Cannabis and Cannabinoid Research
|September 2, 2017
PubMed
Summary

Patients with chronic illnesses use cannabinoids, including FDA-approved products and unregulated medical marijuana. While cannabinoids show therapeutic benefits for specific conditions, recreational use carries risks. Physicians need to be informed about cannabinoid use and discuss it with patients.

Keywords:
cannabinoidsefficacy of cannabinoidsmedical marijuanaphysician prescribing of cannabinoidsrisks of cannabinoids

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.1K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

3.0K

Related Experiment Videos

Last Updated: Feb 23, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

582
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.1K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

3.0K

Area of Science:

  • Pharmacology
  • Internal Medicine
  • Public Health

Background:

  • Many patients with chronic medical conditions utilize cannabinoids.
  • Two cannabinoid products are FDA-approved, but medical marijuana from dispensaries lacks FDA regulation and has variable compound concentrations.
  • Recreational cannabinoid use presents significant potential harms.

Purpose of the Study:

  • To inform physicians about the therapeutic uses and risks of cannabinoids.
  • To provide guidance on clinical approaches for discussing cannabinoid use with patients.
  • To highlight the importance of physician knowledge regarding cannabinoid products.

Main Methods:

  • Literature review of cannabinoid efficacy and safety.
  • Analysis of FDA-approved cannabinoid products versus unregulated medical marijuana.
  • Development of practical clinical recommendations for healthcare providers.

Main Results:

  • Cannabinoids demonstrate efficacy in managing chemotherapy-induced nausea/vomiting, HIV-related appetite loss, certain pain conditions, and multiple sclerosis spasticity.
  • Unregulated medical marijuana poses risks due to uncertain compound concentrations.
  • Recreational cannabinoid use is associated with known serious harms.

Conclusions:

  • Physicians must possess knowledge of cannabinoid products and their effects.
  • Inquiring about and discussing cannabinoid use with patients is crucial for safe and effective care.
  • Clinical strategies are needed to address patient cannabinoid use in chronic illness management.